N-terminal pro-B-type natriuretic peptide and insulin resistance in overweight and obese subjects

Year 2012, Volume: 29 Issue: 3, 179 - 182, 22.10.2012

Aytekin Alcelik , Eyüp Aytekin Mehmet Tosun , Gülali Aktaş , Selim Ayhan Serkan Öztürk Mehmet Özlü Haluk Şavlı Mehmet Yazıcı

https://doi.org/10.5835/jecm.omu.29.03.004

Abstract

Several studies have been conducted to investigate B-type natriuretic peptide (BNP) levels in different obese populations. However, in these studies BNP levels were lower in obese population with an unclear mechanism which has not been explained yet. We sought to investigate the relationship among plasma NT-proBNP levels, obesity and insulin resistance in subjects with no known heart disease. The study population consists of two groups. Subjects with a body mass indexs (BMI) of ≤25 kg/m2 were classified as lean group (LG, n=30), BMI of >25 kg/m2 were classified as overweight and obese group (OG, n=78). Severe hypertension, heart failure, ischemic heart disease, renal or hepatic insufficiency, age >65, pregnancy and malignancy were excluded. There was a
negative correlation between NT-proBNP and weight (r=-0.379, p=0.004) and BMI (r=-0.286, p=0.030) in LG, but there was no such reverse correlation between NT-proBNP and BMI (r=-0.057, p=0.463) in OG. We performed multivariable logistic regression analyses to examine predictors of obesity levels. There were not any significant relation between these predictors and obesity. Insulin levels had a strong association with obesity level however this association was still insignificant (p=0.054). In LG group, there was a negative correlation between NT-proBNP and BMI. There was no correlation between NT-proBNP and homeostatic model assessment (HOMA) and insulin levels (r=-0.035, p=0.789) in LG group, but there was a statistically significant negative correlation between BNP and HOMA (r=-0.219, p=0.009) and insulin levels (r=-0.252, p=0.002) in OG group. Race and ethnicity may contribute this association.

Keywords

NT-proBNP, Obesity, Insulin resistance, Body mass index, Overweight, Waist circumference

Obez ve fazla kilolu kişilerde N-terminal pro-B-tip natriüretik peptid ve insülin direnci

Abstract

Farklı obez popülasyonlarda B-tip natriüretik peptid (BNP) seviyelerini araştıran bazı çalışmalar yapılmıştır. Henüz tam açıklanamayan bir mekanizma ile obezlerde BNP düzeyleri sıklıkla düşük olarak saptanmaktadır. Bilinen kalp hastalığı olmayan bireylerde plazma NT-proBNP seviyeleri, obezite ve insülin direnci arasındaki ilişkiyi araştırmayı amaçladık. Çalışma popülasyonumuz iki gruptan oluşmaktaydı. Vücut kitle indeksi (VKİ) ≤25 kg/m2 olanlar zayıf grubuna (LG, n=30), >25 kg/m2 olanlar ise fazla kilolu ve obez grubuna (OG, n=78) alındı. Ciddi hipertansiyonu, kalp yetmezliği, iskemik kalp hastalığı, böbrek veya karaciğer yetmezliği, malignitesi olan hastalar, gebeler ve 65 yaş üstü hastalar çalışmaya alınmadı. Zayıf hastaların grubunda NT-proBNP ile kilo (r=-0,379, p=0,004) ve VKİ (r=-0,286, p=0,030) arasında negatif bir ilişki varken, obez grupta NT-proBNP ve VKİ arasında böyle bir ters korelasyon saptanmadı. Obezite seviyelerinin belirteçlerini saptamak için çok değişkenli lojistik regresyon analizleri yaptık. Bu belirteçler ile obezite arasında anlamlı ilişki saptanmadı. İnsülin seviyelerinin obezite ile güçlü bir ilişkisi vardı ancak yine de bu ilişki istatistiksel anlamlılık düzeylerine ulaşamıyordu (p=0,054). Zayıf hasta grubunda NT-proBNP ve VKİ arasında ters korelasyon vardı. Aynı grupta NT-proBNP ve homeastatik modelde değerlendirme (HOMA) ve insülin seviyeleri (r=- 0,035, p=0,789) arasında korelasyon yoktu, ancak obez grupta BNP ve HOMA (r=-0,219, p=0,009) ve insulin seviyeleri (r=-0,252, p=0,002) arasında istatistiksel olarak anlamlı ters ilişki vardı. Irk ve etnik köken bu farklılığa katkıda bulunuyor olabilir.

Keywords

NT-proBNP, Obezite, İnsülin direnci, Vücut kitle indeksi, Fazla kilolu, Bel çevresi

References

• Alçelik, A., Cinemre, H., Alçelik, A.G, Özhan, H., Dindar, G. (2007). Brain natriuretic peptides levels in type2 diabetes treated with rosiglitazone. MN Kardiyoloji. 14, 321-327.
• Clerico, A., Giannoni, A., Vittorini, S., Emdin, M., 2012. The paradox of low BNP levels in obesity. Heart Fail. Rev. 17, 81-96.
• Clerico, A., Iervasi, G., Mariani, G., 1999. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm. Metab. Res. 31, 487-498.
• Dessi-Fulgheri, P., Sarzani, R., Tamburrini, P., Moraca, A., Espinosa, E., Cola, G., Giantomassi, L., Rappelli, A., 1997. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J. Hyperten. 15, 1695-1699.
• Hubert, H.B., Feinleib, M., Mcnamara, P.M., Castelli, W.P., 1983. Obesity as an independent risk factor for cardiovascular-disease - a 26-year follow-up of participants in the framingham heart-study. Circulation. 67, 968-977.
• Kalra, P.R., Anker, S.D., Coats, A.J.S., 2001. Water and sodium regulation in chronic heart failure: The role of natriuretic peptides and vasopressin. Cardiovasc. Res. 51, 495-509.
• Khan, A.M., Cheng, S., Magnusson, M., Larson, M.G., Newton-Cheh, C., McCabe, E.L., Coviello, A.D., Florez, J.C., Fox, C.S., Levy, D., Robins, S.J., Arora, P., Bhasin, S., Lam, C.S., Vasan, R.S., Melander, O., Wang, T.J., 2011. Cardiac natriuretic peptides, obesity, and insulin resistance: Evidence from two community-based studies. J. Clin. Endocr. Metab. 96, 3242-3249.
• Koizumi, M., Watanabe, H., Kaneko, Y., Iino, K., Ishida, M., Kosaka, T., Motohashi, Y., Ito, H., 2011. Impact of obesity on plasma B-type natriuretic peptide levels in Japanese community-based subjects. Heart Vessels. 27, 287-294.
• Levin, E.R., Gardner, D.G., Samson, W.K., 1998. Mechanisms of disease - Natriuretic peptides. New Engl. J. Med. 339, 321-328.
• Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., 1985. Homeostasis model assessment - insulin resistance and beta-cell function from fasting plasma-glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
• Olsen, M.H., Hansen, T.W., Christensen, M.K., Gustafsson, F., Rasmussen, S., Wachtell, K., Borch-Johnsen, K., Ibsen, H., Jørgensen, T., Hildebrandt, P., 2005. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension, 46, 660-666.
• Redfield, M.M., Rodeheffer, R.J., Jacobsen, S.J., Mahoney, D.W., Bailey, K.R., Burnett, J.C., 2002. Plasma brain natriuretic peptide concentration: Impact of age and gender. J. Am. Coll. Cardiol. 40, 976-982.
• Tassone, F., Gianotti, L., Rolfo, F., Visconti, G., Borretta, G., Feola, M., 2009. B-type natriuretic peptide levels and insulin resistance in patients with severe ischemic myocardial dysfunction. J. Endocrinol. Invest. 32, 805-809.
• Taylor, J.A., Christenson, R.H., Rao, K., Jorge, M., Gottlieb, S.S., 2006. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am. Heart J. 152, 1071-1076.
• Tosa, S., Watanabe, H., Iino, K., Terui, G., Kosaka, T., Hasegawa, H., Ito, H., 2009. Usefulness of plasma BNP levels as a marker of left ventricular wall stress in obese individuals. Int. Heart J. 50, 173-182.
• Wang, T.J., Larson, M.G., Keyes, M.J., Levy, D., Benjamin, E.J., Vasan, R.S., 2007. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 115, 1345-1353.
• Wang, T.J., Larson, M.G., Levy, D., Benjamin, E.J., Leip, E.P., Omland, T., Wolf, P.A., Vasan, R.S., 2004. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New Engl. J. Med. 350, 655-663.
• Wang, T.J., Larson, M.G., Levy, D., Benjamin, E.J., Leip, E.P., Wilson, P.W.F., Vasan, R.S., 2004. Impact of obesity on plasma natriuretic peptide levels. Circulation. 109, 594-600.